Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Interferon-free therapy alters lipid metabolism, glucose homeostasis in chronic HCV patients

Patients with chronic hepatitis C treated with an interferon-free regimen consisting of sofosbuvir and ribavirin experienced changes in LDL, triglycerides, hemoglobin A1C and metabolic and hepatic lipid gene expression in a study presented at ID Week 2013.

Published
14 October 2013
From
Healio Hepatology
Enter the Nonspecialist: Will Evolving Hepatitis C Therapies Reduce the Need for Specialized Care?

After the advent of the single-tablet regimen, what will be the place of the specialist? We will take a step back as nonspecialists gradually assume a larger role managing patients with few comorbidities and little or no liver disease. For myself, I expect the face of my practice will change; 5 years from now, it will probably be composed entirely of a subset of very complicated patients who may need the benefits of interferon and the experience using it that a specialist provides.

Published
14 October 2013
From
Clinical Care Options (requires registration)
Predicting response to acute hepatitis C treatment in HIV/HCV co-infected people

HIV/HCV co-infected people with higher HCV viral load, lower CD4 cell counts, older age and unfavourable IL28B status may not respond as well to interferon-based treatment for

Published
14 October 2013
By
Liz Highleyman
Daclatasvir works well against hepatitis C either with interferon or in all-oral regimen

A short 12- or 16-week triple regimen of daclatasvir plus pegylated interferon/ribavirin cured more people than a 24-week course of pegylated interferon/ribavirin alone, whilst an interferon-free regimen containing

Published
10 October 2013
By
Liz Highleyman
Idenix Shares Fall as J&J Buys Rival Hepatitis C Therapy

J&J, the world’s largest seller of health-care products, bought rights to a compound from London-based GlaxoSmithKline Plc in a class of drugs called non-structural 5A protein inhibitors. That suggests J&J may be close to ending a partnership with Idenix on its hepatitis C therapies including the NS5a drug samatasvir, Brian Abrahams, an analyst with Wells Fargo & Co., said today in a note to clients.

Published
08 October 2013
From
Bloomberg
Investigational interferon-free regimen demonstrates undetectable hepatitis C virus in all patients reaching end of treatment in ongoing Phase II trial

This ongoing study evaluates a new 12-week interferon-free regimen of Boehringer Ingelheim’s protease inhibitor, faldaprevir*, and non-nucleoside NS5B polymerase inhibitor, deleobuvir*, in combination with Presidio’s pan-genotypic HCV NS5A inhibitor, PPI-668*, with and without ribavirin

Published
08 October 2013
From
Boehringer-Ingelheim press release
Janssen Acquires Investigational NS5A Inhibitor for the Treatment of Hepatitis C from GlaxoSmithKline

Janssen plans to initiate Phase 2 studies to evaluate the use of GSK2336805 in interferon-free combinations with the investigational protease inhibitor simeprevir (TMC435) and TMC647055, Janssen's non-nucleoside polymerase inhibitor, for the treatment of chronic hepatitis C in adult patients with compensated liver disease.

Published
08 October 2013
From
Janssen press release
Achillion's Hepatitis C Drug Still on Hold by U.S. FDA

Achillion Pharmaceuticals Inc. (ACHN) said U.S. regulators are keeping the company’s experimental hepatitis C drug sovaprevir on hold because of abnormal liver results. The shares plunged 45 percent in extended trading.

Published
30 September 2013
From
Bloomberg
Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration

First Phase 2a study includes Presidio's PPI-668 in genotype-1a infected patients; collaboration offers the potential to explore additional HCV genotypes in future trials.

Published
10 September 2013
From
PR Newswire (press release)
Merck demand triggers expanding patent war with Gilead over sofosbuvir

Gilead is rolling out its big legal guns to defend its control of the experimental hepatitis C drug sofosbuvir, one of the most valuable therapies in the industry's late-stage pipeline.

Published
02 September 2013
From
FierceBiotech

Filter by country